RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.

doi:10.1182/blood-2018-05-849893

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.

Blood - 15 Nov 2018

Chapman Michael A, Sive Jonathan, Ambrose John, Roddie Claire, Counsell Nicholas, Lach Anna, Abbasian Mahnaz, Popat Rakesh, Cavenagh Jamie D, Oakervee Heather, Streetly Matthew J, Schey Stephen, Koh Mickey, Willis Fenella, Virchis Andres E, Crowe Josephine, Quinn Michael F, Cook Gordon, Crawley Charles R, Pratt Guy, Cook Mark, Braganza Nivette, Adedayo Toyin, Smith Paul, Clifton-Hadley Laura, Owen Roger G, Sonneveld Pieter, Keats Jonathan J, Herrero Javier, Yong Kwee

Abstract excerpt

Improving outcomes in multiple myeloma will involve not only development of new therapies but also better use of existing treatments. We performed RNA sequencing on samples from newly diagnosed patients enrolled in the phase 2 PADIMAC (Bortezomib, Adriamycin, and Dexamethasone Therapy for Previously Untreated Patients with Multiple Myeloma: Impact of Minimal Residual Disease in Patients with Deferred ASCT) study....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bortezomib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dexamethasone

Share to Doxorubicin

Share to Lenalidomide

Share to Machine Learning

Share to Multiple Myeloma

Share to Proportional Hazards Models

Share to Sequence Analysis, RNA

Source

Open in PubMed Open full text

Identifiers

PMID: 30181174
DOI: 10.1182/blood-2018-05-849893
PMCID: PMC6310235

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.PMID 30181174Read ↗

Machine learning from the CARDAMON trial identifies a carfilzomib-specific mutational response signatureSemantic proximity Read ↗

Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myelomaSemantic proximity Read ↗

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myelomaSemantic proximity Read ↗

Knick-knack PADIMACSemantic proximity Read ↗

RNAseq-Based Machine Learning Models for Prognostication of Multiple MyelomaSemantic proximity Read ↗

A robust gene expression signature to predict proteasome inhibitor benefit in Multiple MyelomaSemantic proximity Read ↗

Inflammatory microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myelomaSemantic proximity Read ↗

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomibSemantic proximity Read ↗

Establishing Measurable Residual Disease Trajectories for Patients on Treatment for Newly Diagnosed Multiple Myeloma as Benchmark for Deployment of T-cell Redirection TherapySemantic proximity Read ↗

Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and DexamethasoneSemantic proximity Read ↗

Dynamic multimodal survival prediction in multiple myeloma integrating gene expression, longitudinal laboratories, and treatment historySemantic proximity Read ↗

Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.